ba g
nk
st in
Te urs
N
TEST BANK FOR
PHARMACOLOGY: A Patient-
Centered Nursing Process
Approach, 10TH EDITION BY
MCCUISTION
, TEST BANK FOR PHARMACOLOGY 10TH EDITION BY MCCUISTION
ba g
nk
st in
Te urs
N
Table of Contents
Chapter 01: The Nursing Process and Patient-Centered Care ............................................................................2
Chapter 02: Drug Development and Ethical Considerations...............................................................................9
Chapter 03: Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics ..................................................17
Chapter 04: Pharmacogenetics .........................................................................................................................31
Chapter 05: Complementary and Alternative Therapies ..................................................................................34
Chapter 06: Pediatric Considerations ...............................................................................................................39
Chapter 07: Geriatric Considerations................................................................................................................46
Chapter 08: Drugs of Abuse ..............................................................................................................................52
Chapter 09: Safety and Quality .........................................................................................................................58
Chapter 10: Drug Administration ......................................................................................................................64
Chapter 11: Drug Calculations ..........................................................................................................................69
Chapter 12: Fluid Volume and Electrolytes.......................................................................................................74
Chapter 13: Vitamin and Mineral Replacement ...............................................................................................83
Chapter 14: Nutritional Support .......................................................................................................................90
Chapter 15: Adrenergic Agonists and Antagonists............................................................................................98
Chapter 16: Cholinergic Agonists and Antagonists .........................................................................................104
Chapter 17: Stimulants ...................................................................................................................................110
Chapter 18: Depressants.................................................................................................................................114
Chapter 19: Antiseizure Drugs ........................................................................................................................120
Chapter 20: Drugs for Parkinson Disease and Alzheimer Disease...................................................................127
Chapter 21: Drugs for Neuromuscular Disorders and Muscle Spasms ...........................................................133
Chapter 22: Antipsychotics and Anxiolytics ....................................................................................................139
Chapter 23: Antidepressants and Mood Stabilizers ........................................................................................146
Chapter 24: Antiinflammatories .....................................................................................................................153
Chapter 25: Analgesics ....................................................................................................................................160
Chapter 26: Antibacterials ..............................................................................................................................167
Chapter 27: Antituberculars, Antifungals, and Antivirals ................................................................................183
Chapter 28: Peptides, Antimalarials, and Anthelmintics ................................................................................191
Chapter 29: HIV- and AIDS-Related Drugs.......................................................................................................194
Chapter 30: Transplant Drugs .........................................................................................................................198
Chapter 31: Vaccines ......................................................................................................................................201
Chapter 32: Anticancer Drugs .........................................................................................................................205
, Chapter 33: Targeted Therapies to Treat Cancer ............................................................................................209
ba g
nk
st in
Te urs
Chapter 34: Biologic Response Modifiers .......................................................................................................212
N
Chapter 35: Upper Respiratory Disorders .......................................................................................................216
Chapter 36: Lower Respiratory Disorders .......................................................................................................220
Chapter 37: Cardiac Glycosides, Antianginals, and Antidysrhythmics ...........................................................226
Chapter 38: Diuretics ......................................................................................................................................233
Chapter 39: Antihypertensives .......................................................................................................................237
Chapter 40: Anticoagulants, Antiplatelets, and Thrombolytics ......................................................................243
Chapter 41: Antihyperlipidemics and Peripheral Vasodilators .......................................................................250
Chapter 42: Gastrointestinal Tract Disorders .................................................................................................255
Chapter 43: Antiulcer Drugs ............................................................................................................................261
Chapter 44: Eye and Ear Disorders .................................................................................................................267
Chapter 45: Dermatologic Disorders...............................................................................................................271
Chapter 46: Pituitary, Thyroid, Parathyroid, and Adrenal Disorders ..............................................................276
Chapter 47: Antidiabetics ...............................................................................................................................283
Chapter 48: Urinary Disorders ........................................................................................................................289
Chapter 49: Pregnancy and Preterm Labor .....................................................................................................294
Chapter 50: Labor, Delivery, and Postpartum.................................................................................................300
Chapter 51: Neonatal and Newborn ...............................................................................................................305
Chapter 52: Women’s Reproductive Health ...................................................................................................307
Chapter 53: Men’s Reproductive Health.........................................................................................................313
Chapter 54: Sexually Transmitted Infections ..................................................................................................317
Chapter 55: Adult and Pediatric Emergency Drugs .........................................................................................320
Chapter 01: The Nursing Process and Patient-Centered Care
McCuistion: Pharmacology: A Patient-Centered Nursing Process Approach, 10th
Edition
MULTIPLE CHOICE
, ba g
nk
st in
Te urs
N
1. A patient who is hospitalized for chronic obstructive pulmonary disease (COPD) wants to go
home. The nurse and the patient discuss the patient’s situation and decide that the patient may
go home when able to perform self-care without dyspnea and hypoxia. This is an example of
which phase of the nursing process?
a. Assessment
b. Evaluation
c. Implementation
d. Planning
ANS: D
Planning involves goal setting, which, for this patient, means being able to perform self-care
activities without dyspnea and hypoxia.
DIF: Cognitive Level: Understanding (Comprehension) TOP: Nursing Process: Planning
MSC: NCLEX: Management of Care
2. A patient will be sent home with a metered-dose inhaler, and the nurse is providing teaching.
Which is a correctly written goal for this process?
a. The nurse will demonstrate the correct use of a metered-dose inhaler to the patient.
b. The nurse will teach the patient how to administer medication with a metered-dose
inhaler.
c. The patient will know how to self-administer the medication using the
metered-dose inhaler.
d. The patient will independently administer the medication using the metered-dose
inhaler at the end of the session.
N
ANS: D
Goals must be patient-centered and clearly state the outcome with a reasonable deadline and
should identify components for evaluation.
DIF: Cognitive Level: Applying (Application) TOP: Nursing Process: Planning
MSC: NCLEX: Management of Care
3. The nurse is developing a plan of care for a patient who has chronic lung disease and hypoxia.
The patient has been admitted for increased oxygen needs above a baseline of 2 L/min. The
nurse develops a goal stating, “The patient will have oxygen saturations of >95% on room air
at the time of discharge from the hospital.” What is wrong with this goal?
a. It cannot be evaluated.
b. It is not measurable.
c. It is not patient-centered.
d. It is not realistic.
ANS: D
This goal is not realistic because the patient is not usually on room air and should not be
expected to attain that goal by discharge from this hospitalization.
DIF: Cognitive Level: Applying (Application) TOP: Nursing Process: Planning
MSC: NCLEX: Management of Care
nk
st in
Te urs
N
TEST BANK FOR
PHARMACOLOGY: A Patient-
Centered Nursing Process
Approach, 10TH EDITION BY
MCCUISTION
, TEST BANK FOR PHARMACOLOGY 10TH EDITION BY MCCUISTION
ba g
nk
st in
Te urs
N
Table of Contents
Chapter 01: The Nursing Process and Patient-Centered Care ............................................................................2
Chapter 02: Drug Development and Ethical Considerations...............................................................................9
Chapter 03: Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics ..................................................17
Chapter 04: Pharmacogenetics .........................................................................................................................31
Chapter 05: Complementary and Alternative Therapies ..................................................................................34
Chapter 06: Pediatric Considerations ...............................................................................................................39
Chapter 07: Geriatric Considerations................................................................................................................46
Chapter 08: Drugs of Abuse ..............................................................................................................................52
Chapter 09: Safety and Quality .........................................................................................................................58
Chapter 10: Drug Administration ......................................................................................................................64
Chapter 11: Drug Calculations ..........................................................................................................................69
Chapter 12: Fluid Volume and Electrolytes.......................................................................................................74
Chapter 13: Vitamin and Mineral Replacement ...............................................................................................83
Chapter 14: Nutritional Support .......................................................................................................................90
Chapter 15: Adrenergic Agonists and Antagonists............................................................................................98
Chapter 16: Cholinergic Agonists and Antagonists .........................................................................................104
Chapter 17: Stimulants ...................................................................................................................................110
Chapter 18: Depressants.................................................................................................................................114
Chapter 19: Antiseizure Drugs ........................................................................................................................120
Chapter 20: Drugs for Parkinson Disease and Alzheimer Disease...................................................................127
Chapter 21: Drugs for Neuromuscular Disorders and Muscle Spasms ...........................................................133
Chapter 22: Antipsychotics and Anxiolytics ....................................................................................................139
Chapter 23: Antidepressants and Mood Stabilizers ........................................................................................146
Chapter 24: Antiinflammatories .....................................................................................................................153
Chapter 25: Analgesics ....................................................................................................................................160
Chapter 26: Antibacterials ..............................................................................................................................167
Chapter 27: Antituberculars, Antifungals, and Antivirals ................................................................................183
Chapter 28: Peptides, Antimalarials, and Anthelmintics ................................................................................191
Chapter 29: HIV- and AIDS-Related Drugs.......................................................................................................194
Chapter 30: Transplant Drugs .........................................................................................................................198
Chapter 31: Vaccines ......................................................................................................................................201
Chapter 32: Anticancer Drugs .........................................................................................................................205
, Chapter 33: Targeted Therapies to Treat Cancer ............................................................................................209
ba g
nk
st in
Te urs
Chapter 34: Biologic Response Modifiers .......................................................................................................212
N
Chapter 35: Upper Respiratory Disorders .......................................................................................................216
Chapter 36: Lower Respiratory Disorders .......................................................................................................220
Chapter 37: Cardiac Glycosides, Antianginals, and Antidysrhythmics ...........................................................226
Chapter 38: Diuretics ......................................................................................................................................233
Chapter 39: Antihypertensives .......................................................................................................................237
Chapter 40: Anticoagulants, Antiplatelets, and Thrombolytics ......................................................................243
Chapter 41: Antihyperlipidemics and Peripheral Vasodilators .......................................................................250
Chapter 42: Gastrointestinal Tract Disorders .................................................................................................255
Chapter 43: Antiulcer Drugs ............................................................................................................................261
Chapter 44: Eye and Ear Disorders .................................................................................................................267
Chapter 45: Dermatologic Disorders...............................................................................................................271
Chapter 46: Pituitary, Thyroid, Parathyroid, and Adrenal Disorders ..............................................................276
Chapter 47: Antidiabetics ...............................................................................................................................283
Chapter 48: Urinary Disorders ........................................................................................................................289
Chapter 49: Pregnancy and Preterm Labor .....................................................................................................294
Chapter 50: Labor, Delivery, and Postpartum.................................................................................................300
Chapter 51: Neonatal and Newborn ...............................................................................................................305
Chapter 52: Women’s Reproductive Health ...................................................................................................307
Chapter 53: Men’s Reproductive Health.........................................................................................................313
Chapter 54: Sexually Transmitted Infections ..................................................................................................317
Chapter 55: Adult and Pediatric Emergency Drugs .........................................................................................320
Chapter 01: The Nursing Process and Patient-Centered Care
McCuistion: Pharmacology: A Patient-Centered Nursing Process Approach, 10th
Edition
MULTIPLE CHOICE
, ba g
nk
st in
Te urs
N
1. A patient who is hospitalized for chronic obstructive pulmonary disease (COPD) wants to go
home. The nurse and the patient discuss the patient’s situation and decide that the patient may
go home when able to perform self-care without dyspnea and hypoxia. This is an example of
which phase of the nursing process?
a. Assessment
b. Evaluation
c. Implementation
d. Planning
ANS: D
Planning involves goal setting, which, for this patient, means being able to perform self-care
activities without dyspnea and hypoxia.
DIF: Cognitive Level: Understanding (Comprehension) TOP: Nursing Process: Planning
MSC: NCLEX: Management of Care
2. A patient will be sent home with a metered-dose inhaler, and the nurse is providing teaching.
Which is a correctly written goal for this process?
a. The nurse will demonstrate the correct use of a metered-dose inhaler to the patient.
b. The nurse will teach the patient how to administer medication with a metered-dose
inhaler.
c. The patient will know how to self-administer the medication using the
metered-dose inhaler.
d. The patient will independently administer the medication using the metered-dose
inhaler at the end of the session.
N
ANS: D
Goals must be patient-centered and clearly state the outcome with a reasonable deadline and
should identify components for evaluation.
DIF: Cognitive Level: Applying (Application) TOP: Nursing Process: Planning
MSC: NCLEX: Management of Care
3. The nurse is developing a plan of care for a patient who has chronic lung disease and hypoxia.
The patient has been admitted for increased oxygen needs above a baseline of 2 L/min. The
nurse develops a goal stating, “The patient will have oxygen saturations of >95% on room air
at the time of discharge from the hospital.” What is wrong with this goal?
a. It cannot be evaluated.
b. It is not measurable.
c. It is not patient-centered.
d. It is not realistic.
ANS: D
This goal is not realistic because the patient is not usually on room air and should not be
expected to attain that goal by discharge from this hospitalization.
DIF: Cognitive Level: Applying (Application) TOP: Nursing Process: Planning
MSC: NCLEX: Management of Care
